<DOC>
	<DOCNO>NCT00150618</DOCNO>
	<brief_summary>The purpose study determine efficacy SPD503 compare placebo treatment child adolescent age 6-17 ADHD .</brief_summary>
	<brief_title>Safety Efficacy SPD503 Treating ADHD Children Adolescents Aged 6-17</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Subjects primary diagnosis ADHD Females childbearing potential must negative serum beta human chorionic gonadotropin ( HCG ) pregnancy test Male nonpregnant female subject agree comply applicable contraceptive requirement Subject current , uncontrolled , comorbid psychiatric diagnosis significant symptom severe comorbid Axis II disorder severe Axis I disorder Subject weigh less 55 lb morbidly overweight BMI = &gt; 35 Subject history seizure last 2 year serious tic disorder , include Tourette 's Disorder Subject pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>